Helicobacter pylori: new developments and treatments. Journal Articles

abstract

• The authors highlight new developments in research on Helicobacter pylori. There is now consensus that all patients with newly diagnosed or recurrent duodenal or gastric ulcers who have a positive test result for H. pylori should be treated for the infection. Patients presenting with complications of ulcers, such as bleeding, should also be treated. H. pylori has recently been classified as a definite human carcinogen by the International Agency for Research on Cancer. In treatment, new combination regimens, consisting of 3 or 4 different drugs, cure the infection in more than 80% of patients. Currently, the best combinations are: (1) omeprazole (or another proton-pump inhibitor), clarithromycin and metronidazole, (2) omeprazole (or another proton-pump inhibitor), clarithromycin and amoxicillin, (3) bismuth subsalicylate, tetracycline and metronidazole, and (4) omeprazole, bismuth subsalicylate, tetracycline and metronidazole.

authors

• Veldhuyzen van Zanten, SJ
• Sherman, PM
• Hunt, Richard H

status

• published 

publication date

• June 1, 1997

has subject area

• 11 Medical and Health Sciences (FoR)
• Algorithms (MeSH)
• Anti-Bacterial Agents (MeSH)
• Anti-Ulcer Agents (MeSH)
• Clarithromycin (MeSH)
• Drug Therapy, Combination (MeSH)
• General & Internal Medicine (Science Metrix)
• Helicobacter Infections (MeSH)
• Helicobacter pylori (MeSH)
• Humans (MeSH)
• Omeprazole (MeSH)
• Peptic Ulcer (MeSH)

published in

• CANADIAN MEDICAL ASSOCIATION JOURNAL  Journal

keywords

• Algorithms
• Anti-Bacterial Agents
• Anti-Ulcer Agents
• Clarithromycin
• Drug Therapy, Combination
• Helicobacter Infections
• Helicobacter pylori
• Humans
• Omeprazole
• Peptic Ulcer

start page

• 1565

end page

• 1574

volume

• 156

issue

• 11